Comparison of clinical trials with sildenafil, tadalafil and vardenafil in erectile dysfunction
Erectile dysfunction (ED) affects up to 50% of men, between 40 and 70 years of age. In the first major trial of sildenafil in ED, at 24 weeks, improved erections were reported by 77 and 84% of men taking sildenafil 50 and 100mg, respectively. Subsequently, sildenafil has been reported to be effective in men with ED associated with diabetes and prostate cancer, and in psychogenic ED. Sildenafil is safe in men with coronary artery disease, provided it is not used with the nitrates (a contraindication). The most commonly reported adverse effects with sildenafil are headache, flushing and dyspepsia. tadalafil is more potent and more selective than sildenafil at inhibiting phosphodiesterase-5. tadalafil is similarly effective to sildenafil in the treatment of ED. The only advantage that tadalafil has over sildenafil is that it does not inhibit phosphodiesterase-6 to alter colour perception, a rare side effect which sometimes occurs with sildenafil. vardenafil has a longer duration of action than sildenafil and tadalafil. vardenafil is similarly effective as sildenafil in the treatment of ED. In comparison studies, vardenafil is preferred to sildenafil (50/100mg) by men with ED, possibly because of its longer duration of action. Of the phosphodiesterase inhibitors, vardenafil may displace sildenafil as the drug of choice among men with ED.
Comment in
Perimenis P. Perimenis P. Expert Opin Pharmacother. 2005 Jan;6(1):1-2. doi: 10.1517/14656566.6.1.1. Expert Opin Pharmacother. 2005. PMID: 15709877 No abstract available.
Similar articles
Doggrell S. Doggrell S. Int J Impot Res. 2007 May-Jun;19(3):281-95. doi: 10.1038/sj.ijir.3901525. Epub 2006 Dec 21. Int J Impot Res. 2007. PMID: 17183346 Review.
Mulhall JP, McLaughlin TP, Harnett JP, Scott B, Burhani S, Russell D. Mulhall JP, et al. J Sex Med. 2005 Nov;2(6):848-55. doi: 10.1111/j.1743-6109.2005.00149.x. J Sex Med. 2005. PMID: 16422809
Mulhall JP, Chopra I, Patel D, Hassan TA, Tang WY. Mulhall JP, et al. J Sex Med. 2020 May;17(5):941-948. doi: 10.1016/j.jsxm.2020.01.027. Epub 2020 Mar 3. J Sex Med. 2020. PMID: 32144034 Free PMC article.
Jannini EA, Isidori AM, Gravina GL, Aversa A, Balercia G, Bocchio M, Boscaro M, Carani C, Corona G, Fabbri A, Foresta C, Forti G, Francavilla S, Granata AR, Maggi M, Mansani R, Palego P, Spera G, Vetri M, Lenzi A; Endotrial Study Group. Jannini EA, et al. J Sex Med. 2009 Sep;6(9):2547-60. doi: 10.1111/j.1743-6109.2009.01375.x. Epub 2009 Jun 29. J Sex Med. 2009. PMID: 19570039 Clinical Trial.
Kuthe A. Kuthe A. Curr Opin Urol. 2003 Sep;13(5):405-10. doi: 10.1097/00042307-200309000-00008. Curr Opin Urol. 2003. PMID: 12917517 Review.
Cited by
Afshar B, Amini L, Hasani M, Jahanfar S, Massood Nabavi S. Afshar B, et al. Int J Reprod Biomed. 2022 May 23;20(4):241-254. doi: 10.18502/ijrm.v20i4.10897. eCollection 2022 Apr. Int J Reprod Biomed. 2022. PMID: 35822180 Free PMC article. Review.
Ahmed MM, Anwer MK, Soliman GA, Aldawsari MF, Mohammed AA, Alshehri S, Ghoneim MM, Alali AS, Alshetaili A, Alalaiwe A, Bukhari SI, Zafar A. Ahmed MM, et al. PeerJ. 2022 May 26;10:e13482. doi: 10.7717/peerj.13482. eCollection 2022. PeerJ. 2022. PMID: 35642201 Free PMC article.
Goberdhan S, Blachman-Braun R, Nackeeran S, Masterson TA 3rd, Ramasamy R. Goberdhan S, et al. World J Urol. 2022 Jul;40(7):1799-1803. doi: 10.1007/s00345-022-04005-3. Epub 2022 Apr 25. World J Urol. 2022. PMID: 35469100 Free PMC article.
Kumar M, Pathade AD, Gupta SV, Goyal S, Rath D, Thakre M, Sanmukhani J, Mittal R. Kumar M, et al. Int J Urol. 2022 Apr;29(4):351-359. doi: 10.1111/iju.14785. Epub 2022 Jan 26. Int J Urol. 2022. PMID: 35080051 Free PMC article. Clinical Trial.
Ab Ghani NS, Emrizal R, Makmur H, Firdaus-Raih M. Ab Ghani NS, et al. Comput Struct Biotechnol J. 2020;18:2931-2944. doi: 10.1016/j.csbj.2020.10.013. Epub 2020 Oct 21. Comput Struct Biotechnol J. 2020. PMID: 33101604 Free PMC article.
Kumar M, Pathade AD, Gupta SV, Goyal S, Rath D, Thakre M, Sanmukhani J, Mittal R. Kumar M, et al. Int J Urol. 2022 Apr;29(4):351-359. doi: 10.1111/iju.14785. Epub 2022 Jan 26. Int J Urol. 2022. PMID: 35080051 Free PMC article. Clinical Trial.
Comparison of clinical trials with sildenafil, tadalafil and vardenafil in erectile dysfunction
Erectile dysfunction (ED) affects up to 50% of men, between 40 and 70 years of age. In the first major trial of sildenafil in ED, at 24 weeks, improved erections were reported by 77 and 84% of men taking sildenafil 50 and 100mg, respectively. Subsequently, sildenafil has been reported to be effective in men with ED associated with diabetes and prostate cancer, and in psychogenic ED. Sildenafil is safe in men with coronary artery disease, provided it is not used with the nitrates (a contraindication). The most commonly reported adverse effects with sildenafil are headache, flushing and dyspepsia. tadalafil is more potent and more selective than sildenafil at inhibiting phosphodiesterase-5. tadalafil is similarly effective to sildenafil in the treatment of ED. The only advantage that tadalafil has over sildenafil is that it does not inhibit phosphodiesterase-6 to alter colour perception, a rare side effect which sometimes occurs with sildenafil. vardenafil has a longer duration of action than sildenafil and tadalafil. vardenafil is similarly effective as sildenafil in the treatment of ED. In comparison studies, vardenafil is preferred to sildenafil (50/100mg) by men with ED, possibly because of its longer duration of action. Of the phosphodiesterase inhibitors, vardenafil may displace sildenafil as the drug of choice among men with ED.
Perimenis P. Perimenis P. Expert Opin Pharmacother. 2005 Jan;6(1):1-2. doi: 10.1517/14656566.6.1.1. Expert Opin Pharmacother. 2005. PMID: 15709877 No abstract available.
Erectile dysfunction (ED) affects up to 50% of men, between 40 and 70 years of age. In the first major trial of sildenafil in ED, at 24 weeks, improved erections were reported by 77 and 84% of men taking sildenafil 50 and 100mg, respectively. Subsequently, sildenafil has been reported to be effective in men with ED associated with diabetes and prostate cancer, and in psychogenic ED. Sildenafil is safe in men with coronary artery disease, provided it is not used with the nitrates (a contraindication). The most commonly reported adverse effects with sildenafil are headache, flushing and dyspepsia. tadalafil is more potent and more selective than sildenafil at inhibiting phosphodiesterase-5. tadalafil is similarly effective to sildenafil in the treatment of ED. The only advantage that tadalafil has over sildenafil is that it does not inhibit phosphodiesterase-6 to alter colour perception, a rare side effect which sometimes occurs with sildenafil. vardenafil has a longer duration of action than sildenafil and tadalafil. vardenafil is similarly effective as sildenafil in the treatment of ED. In comparison studies, vardenafil is preferred to sildenafil (50/100mg) by men with ED, possibly because of its longer duration of action. Of the phosphodiesterase inhibitors, vardenafil may displace sildenafil as the drug of choice among men with ED.
Similar articles
Clinical Trial.
09.06.2023 20:39:04
2023-06-09 20:39:04